Madrigal Pharmaceuticals, Inc.

MDGL Healthcare Biotechnology

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024. In the quarter to June 2026, revenue grew 71.2%, EPS fell 32.9%, free cash flow grew 140.5% and total debt rose 187.9%, each against the same quarter a year earlier.

449.74 10.07 −2.19%
Market cap
$10.6B
P/E
0.0×
Fwd P/E
−71.3×
Dividend yield
—
F-score
n/a
Altman Z
10.48
Beneish M
0.50
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
(288.28) (465.89) (373.63) (295.35) (241.85) (202.24) (83.95) (32.81) (31.15) (26.39)
Depreciation & Amortization
6.32 2.79 2.94 1.26 0.41 0.47 0.11 0.10 0.08 0.00
Non Cash Items (Other)
100.91 79.88 49.74 31.63 26.87 20.73 22.76 13.49 3.25 9.89
Accounts Receivable Change
(80.65) (53.82) — — — — — — — 0.01
Change in inventories
(36.98) (34.07) — — — — — — — —
Accounts Payable Change
5.28 15.56 4.21 2.45 20.36 (0.16) (1.31) 0.56 0.92 (0.13)
Change in payables and accrued liability
137.87 10.62 (6.93) 36.41 10.61 23.51 20.43 (5.84) 4.09 (2.27)
Change in other assets and liabilities
(34.02) (10.64) (0.55) (1.26) (0.32) 0.14 0.33 (1.00) 0.50 1.29
Operating Cash Flow
(189.55) (455.57) (324.23) (224.86) (183.92) (157.56) (41.62) (25.51) (22.32) (17.61)
Capital expenditures
(0.47) (1.46) (1.48) (0.22) (0.21) (0.33) (0.17) (0.02) (0.12) 0.70
Change in intangibles (net)
(3.00) (5.00) 0.00 0.00 — — — — — —
Net Aquisitions
— — — — — — — — — 5.85
Short Term Investments Change (Net)
35.79 (267.92) (501.04) 206.90 (4.85) 160.11 30.88 (380.05) (21.88) 15.37
Other investing activities
— — — — — — — — — 0.08
Investing cash flow
32.32 (274.39) (502.52) 206.69 (5.05) 159.78 30.71 (380.08) (22.01) 21.99
Repayment/Issuance of Debt (Net)
228.34 — 65.00 50.00 1.03 — — — — 8.50
Equity Repurchase (Common, Net)
38.06 735.06 530.48 264.34 170.21 5.09 0.24 314.34 173.81 5.95
Other financial activities
(10.41) — (0.36) (0.89) 26.87 20.73 22.76 13.49 3.25 9.89
Financing cash flow
255.98 735.06 595.12 313.45 171.24 5.09 0.24 314.34 173.81 14.45
Change in Cash
98.76 5.10 (231.63) 295.28 (17.73) 7.31 (10.68) (91.25) 129.48 18.84
Beginning Cash
105.02 99.92 331.55 36.27 54.00 46.70 57.38 148.63 19.15 0.31
Ending Cash
203.78 105.02 99.92 331.55 36.27 54.00 46.70 57.38 148.63 19.15
Stock Based Compensation
98.13 79.88 49.74 31.63 26.87 20.73 22.76 13.49 3.25 8.68
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 — — — — — — — —
Assets Liabilities Change (Total)
(8.50) (72.34) (3.28) 37.60 30.65 23.48 19.45 (6.28) 5.51 (1.11)
Investments Change (Net)
35.79 (267.92) (501.04) 206.90 (4.85) 160.11 30.88 (380.05) (21.88) 15.37
Issuance/Purchase of Shares
38.06 735.06 530.48 264.34 170.21 5.09 0.24 314.34 173.81 5.95
Other line items
Revenue per Employee
1.05 0.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Fold the line items

In millions of $ except per-share values · columns are period end dates